Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.

Pharmacogenomics - 1 Aug 2018

Sim Sarah, Lövrot John, Lindh Jonatan D, Bergh Jonas, Xie Hanjing

Abstract excerpt

AIM: We investigated the interaction of CYP2C19 and CYP2D6 genotype on clinical outcome in tamoxifen-treated breast cancer patients. MATERIALS & METHODS: A cohort of 306 patients on tamoxifen treatment for a minimum of 1 year were employed to analyze the effect of genotype-predicted phenotype on relapse-free survival. RESULTS & CONCLUSION: We show that the group with worst outcome and highest risk of relapse is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Disease-Free Survival

Share to Neoplasm Recurrence, Local

Share to Premenopause

Share to Tamoxifen

Source

Identifiers

PMID: 30022682
DOI: 10.2217/pgs-2018-0089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.PMID 30022682Read ↗

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.Semantic proximity Read ↗

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?Semantic proximity Read ↗

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.